Key Highlights

  • ZBIO shares traded up 10.97% to $29.64, versus a prior close of $26.71.
  • Morgan Stanley started coverage at Equalweight with a $32 target.
  • Phase 3 INDIGO extension data in IgG4-related disease were upbeat.
  • The PDUFA date for obexelimab is May 27, 2027.
  • Phase 2 multiple sclerosis data are due Thursday.

Morgan Stanley Starts Coverage and Sees Obexelimab as Approvable

Zenas BioPharma (NASDAQ:ZBIO) shares traded up 10.97% to $29.64 after Morgan Stanley started coverage at Equalweight with a $32 target, saying obexelimab looks approvable in IgG4-related disease. The initiation joined upbeat Phase 3 INDIGO extension data and a PDUFA date of May 27, 2027.

Consensus is Moderate Buy, with targets running from the mid-$40s to the mid-$50s across other firms.

Thursday's Multiple Sclerosis Data Add Near-Term Risk and Reward

Phase 2 data for obexelimab and orelabrutinib in multiple sclerosis are expected on Thursday. Obexelimab is a bifunctional CD19 by FcgammaRIIb antibody that inhibits B-cell activity without depleting the cells, while orelabrutinib is a BTK inhibitor in Phase 3 development for progressive multiple sclerosis.

Wider Losses and a History of Dilution Remain Concerns

The last quarterly loss was wider than expected, and the company has a history of dilution. Earnings per share are a loss of $8.99. Zenas has a market capitalization of about $1.93 billion and a 52-week range of $13.50 to $44.60. Volume was light.

The healthcare sector ETF is near a 52-week high, which has supported shares of clinical-stage biotech names.

PDUFA Date and Phase 2 Results Define the Road Ahead

Investors will track the multiple sclerosis readout this week and the May 27, 2027 FDA decision date. Reliance on a few assets means each data point carries weight.